Oral cancer, a subtype of head and neck cancer, is characterized by increased infil- 
| INTRODUC TI ON
Head and neck cancer accounts for approximately 4% of all malignancies worldwide and 5% mortality of all cancers.
1 Notably, the incidence of oral cancer ranks among the top three cancer types in several Asia-Pacific countries. 2 More than 90% of head and neck cancer are squamous cell carcinomas, arising from the epithelial cells that line the mucosal surfaces of the head and neck regions, including the oral cavity. 3 The main etiological factors include tobacco and alcohol abuse, betel quid chewing or human papillomavirus infection. 4 Early diagnosis of head and neck cancer is relatively feasible, but presentation with advanced disease is not uncommon. 5 The fact that few therapeutic options other than surgery, standard cytotoxic chemotherapy, and radiation are available significantly impede improvement of the 5-year survival rate.
6
Tumor stromal cells including cells of the immune system modulate cancer development and progression. 7 Regulatory T (Treg) cells that express the transcription factor FOXP3 8 are often found at elevated levels in tumor lesions and are essential for the prevention of autoimmunity and the maintenance of immune homeostasis.
9
Moreover, the density of tumor-infiltrating Treg cells has prognostic value 10, 11 and can be negatively or positively correlated with the outcome of several malignancies, depending on the cancer type.
12
An increase in Treg has been reported not only in peripheral blood and draining lymph nodes but also in the primary tumor microenvironment. 13 The phenotype and functions of Treg are modulated by the local milieu of cytokines, metabolites, and catabolites in their surrounding environment. 14, 15 Among the 10 cancer types with the highest overall immune infiltration scores, head and neck cancer shows the highest score of Treg infiltration, therefore providing a strong rationale for the treatment of these tumors with immunotherapy modalities by targeting Tregs. 16 Although Treg infiltration and accumulation correlate with cancer patient prognosis, it is not entirely understood how Tregs are recruited to tumor lesions and the microenvironment in head and neck cancer.
Chemokine-mediated chemotaxis in the tumor milieu is one possible mechanism responsible for Treg trafficking. 13 The C-C chemokine receptor type 4 (CCR4) is expressed preferentially in human 
| MATERIAL S AND ME THODS

| Materials
Culture media, FBS, Lipofectamine 2000, TRIzol, and RT-qPCR reagents were from Thermo Fisher Scientific. Oligonucleotide primers for sequencing and RT-qPCR (Table S1) were from IDT. pLKO_AS2.
zeo and plasmids bearing shRNAs (Table S2) were from National RNAi Core facility in Academia Sinica, Taiwan. Recombinant human IL-1β was from PeproTech. Pyrrolidine dithiocarbamate (PDTC) was from Tocris Bioscience. Sources of antibodies are listed in Table S3 . 
| Oral cancer patient samples
| Mice
Male C57BL/6, NOD-SCID, C3H/HeN or BALB/c athymic mice at 6-8 weeks old were purchased from the National Laboratory Animal 
| Animal cancer models
| Luciferase reporter assay
We cloned the proximal promoter spanning −1191 ~ +34 (tran- promoter reporter were treated with vehicle or IL-1β at 50-100 ng/ mL for 24 hours followed by luciferase activity assays. HA-p65, an NF-κB subunit, was used as a positive control for NF-κB activation.
To examine the effects of p65 and IL-1β on CCL22 promoter activity, we transfected Ca9-22 cells with CCL22 promoter reporter followed by 24 hours of incubation with CAF-conditioned media (CM) in the presence or absence of PDTC, a selective NF-κB inhibitor, or CM collected from control shLuc or IL1B-knockdown (shIL1B) CAF.
| Statistical analyses
Survival time was calculated from surgical resection until the last follow-up appointment of each patient (overall survival) or until the patient succumbed to the disease (disease-free survival).
Recurrence was indicated as * (P < .05), ** (P < .01), or *** (P < .001).
| Online supporting methods
Online Supporting Methods.
| RE SULTS
| Increase in CCL22 expression is associated with poor prognosis in oral cancer patients
Neutralization of CCR4 receptors selectively depleted Tregs.
18
Furthermore, CCL22 and CCL17 were reported to bind CCR4 24 and
were involved in the recruitment of Tregs. 25 We first analyzed the expression of both cytokines in the head and neck cancer patient cohorts in the ONCOMINE database 26 and found that only CCL22 is statistically upregulated in the Estilo Head-Neck cohort ( Figure S1 ). As a result of the limited size in these patient cohorts, we next used RT-qPCR to analyze CCL22 mRNA expression of 93 oral cancer patients recruited at NCKUH. As shown in Figure 1A , a statistically significant increase in CCL22 mRNA expression was observed. We then divided the patients into two groups, high (>median) and low (≤median), based on the median CCL22 mRNA expression in these patients. Kaplan-Meier survival curve analysis was used to examine the correlation between CCL22 expression and overall patient survival, and recurrence-and disease-free survival. We found that high CCL22 expression was found mostly in younger patients (62.2% vs 37.8% in Table 2 ) and that this high CCL22
expression showed no correlation with overall and recurrence-free survival ( Figure S2 ). Nonetheless, the data show a trend indicating that high CCL22 expression correlates with reduced disease-free survival rates ( Figure 1B ), suggesting a role of CCL22 deregulation in oral cancer.
| Expression of CCL22 positively correlates with FOXP3 expression in oral cancer patients
CCL22 was previously shown to regulate Treg trafficking in ovarian cancer. 22 To examine the clinical implication of CCL22 deregulation and its association with Treg recruitment in clinical specimens from oral cancer patients, we first analyzed mRNA expression of FOXP3, a marker for Tregs, in 93 oral cancer patients by using RT-qPCR.
We found that expression of FOXP3 was significantly elevated in oral cancer tissues relative to adjacent normal tissues ( Figure 1C ).
Moreover, the expression of CCL22 mRNA was positively associated with that of FOXP3 mRNA in both The Cancer Genome Atlas (TCGA; N = 496, Pearson r = 0.3867; P < .001) and NCKU head and neck cancer cohorts (N = 93, Pearson r = 0.8281; P < .001) ( Figure 1D ). Based on these data, we hypothesize that CCL22 is a major chemokine involved in Treg recruitment in oral cancer patients.
| Ectopic CCL22 expression increased migration and invasion of oral cancer cells
To address the role of CCL22 deregulation in oral cancer cells, we first carried out RT-qPCR to quantify mRNA expression of CCL22 and its receptor, CCR4, in six oral cancer cell lines (Figure 2A ). 
| Silencing CCL22 expression reduced oral cancer cell proliferation, migration, and invasion
We also used gene silencing to determine the impact of CCL22 de- 
| CCL22 manipulation altered in vivo xenograft tumorigenesis
To address the intratumoral role of CCL22 expression in tumorigenesis, we s.c. injected control or Ca9-22-CCL22-OE cells in immunocompromised NOD-SCID mice. Our data indicated that CCL22 F I G U R E 1 Increase in CCL22 expression is associated with a reduced disease-free survival rate as well as an increase in FOXP3 expression in oral cancer patients. mRNA levels of CCL22 (A) or FOXP3 (C) in oral cancer tissues from patients were determined by RT-qPCR. Data represent mean ± SEM (N = 93). *p < .05 or ** p < .01 vs normal tissues. B, Kaplan-Meier survival curve analysis for disease-free survival of 93 oral cancer patients at NCKUH was carried out following stratification into two groups based on median CCL22 mRNA expression levels. Patients expressing higher CCL22 mRNA had a reduced disease-free survival rate when compared with those expressing lower CCL22 (p = Based on the median expression of CCL22 mRNA, the 93 oral cancer patients were divided into two groups, low (smaller or equal to median) and high (greater than median). Chi-squared test was used to compare the clinicopathological characteristics between high and low groups (*P < .05). These squamous cell carcinoma-like lesions with invasive fronts were detected only in drug-treated but not in the control mice ( Figure S6 ).
| Treg-associated
As Foxp3 is considered to be a lineage-specific transcription factor of 
| Cancer-associated fibroblast-derived IL-1β induces CCL22 expression by NF-κB activation
Cancer-associated fibroblasts are one of the major components in tumor stroma and play an important role in maintaining an optimal microenvironment to support cancer cell survival and proliferation.
In addition to the widely used biomarker, α-smooth muscle actin (α-SMA), fibroblast-specific protein-1 (FSP-1) is also expressed in CAF. 30 CAF produce cytokines or chemokines that foster tumor growth and the recruitment of immune cells. 31 Following microscopy and Western blot validation of fibroblast markers in CAF and adjacent normal fibroblasts (NF) (Figure S7A ), we first carried out in vitro However, a selective inhibitor of NF-κB, PDTC, or knocking down IL-1B (shIL1B), significantly compromised the ability of CAF-CM to transactivate CCL22 promoter activity ( Figure 6D ). Taken together, our results support the conclusion that CAF-derived IL-1β induces CCL22 expression in an NF-κB-dependent way in oral cancer.
| D ISCUSS I ON
In past decades, limited therapeutic options have impeded significant improvement of the 5-year survival rate for head and neck cancer. Among 10 cancer types with the highest overall immune infiltration scores, head and neck cancer has the highest score for Treg infiltration, thereby providing a strong rationale for treating these (Table S1) . Actin is an internal loading control. D, Volume of shLuc-or shCCL22-expressing (clone 1) xenografted tumors. *P < .05; **P < .01 vs shLuc. mRNA expression is expressed at an elevated level in oral cancer patients compared to their normal cohorts, and this increase compromises its disease-free survival.
We also observed an association with a borderline significance (P = .08) between an increase in CCL22 expression in patient tumorous tissues with reduced disease-free survival. Despite that the immunopositivity of CCR4 and one of its ligands, CCL22, was previously shown to mediate lymph node metastasis in head and neck cancer, 23 we were unable to detect any clinical association of CCL22 mRNA expression with patients' clinicopathological characteristics, except age ( Table 2 ). The different observations could be as a result of the methods used for measuring CCL22 expression, namely, RTqPCR analysis in our study and immunohistochemical staining in the study of Tsujikawa et al. and IL1B knockdown (shLuc vs shIL1B) on the ability of CAF-conditioned media (CM) to induce CCL22 promoter activity. Data represent mean ± SD. *P < .05, **P < .01, ***P < .001 vs control. E, Model depicting the autocrine and paracrine effects of CCL22 deregulation in oral cancer and tumor stroma oral cancer ( Figure 5C ). Overall, these data lend strong support to the notion that an increase in CCL22 expression mediates the re- Oral cancer patients often have elevated levels of inflammatory cytokines such as IL-1β or TGF-β in their saliva, which are in close contact with cancer cells in the oral cavity. 36, 37 These cytokines either alone or together enhanced CCL22 expression. 32, 38 CAFs constitute a significant portion of the reactive tumor stroma and play a crucial role in tumor progression through direct cell-cell contacts or by the secretion of cytokines, chemokines, and growth factors. 39 Among these cytokines, IL-1β was the most differentially expressed in CAFs isolated from oral cancer tissues ( Figure 6A ). Although MCP-1 could also be induced by IL-1β-treated fibroblasts 40 and mediated the crosstalk between fibroblasts and breast cancer cells, 41 we failed to detect the differential expression of MCP1 in the pairwise comparison of NF and CAF ( Figure S7C) . Moreover, the expression of IL1B mRNA was positively associated with that of CCL22 mRNA in clinical specimens and drug-induced oral cancer lesions ( Figure 6B ). Our promoter reporter assays further showed that CAF-derived IL-1β potently induces CCL22 reporter activity in a way that is dependent on NF-κB activity ( Figure 6C,D) . Although ~58% of isolated CAF lines with activating phosphorylation of NF-κB ( Figure S10) and a borderline significance of increased IL-1B expression in CAF relative to paired NF ( Figure 6B , P = .047) were detected, we cannot rule out the possibility of losing the in vivo properties during in vitro propagation of proinflammatory CAFs 42 and the influence of tumor cells in the tumor microenvironment.
41
Our study supports an oncogenic function of CCL22 in oral cancer through both autonomous and non-autonomous actions, leading to a potential application of using serum CCL22 as a marker for oral cancer prognosis. Furthermore, we rationalize that a better understanding of the crosstalk between Tregs and oral cancer cells will be useful in justifying targeting the IL-1β-CCL22-CCR4 axis as a viable option for treating oral cancer.
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